Last updated: September 3, 2026
Lusutrombopag, marketed as Mulpleta in the United States and Japan, is a thrombopoietin receptor agonist used to raise platelet counts in adults with chronic liver disease who are scheduled for an invasive procedure. Its commercial position is narrow but defensible: the drug addresses a defined pre-procedure population, has a short treatment course, and competes mainly with avatrombopag and platelet transfusion rather than with chronic-use hematology products.
Shionogi retains the economic interest in the product. Public filings do not report Mulpleta revenue as a separate line item, so its exact contribution to Shionogi's consolidated sales cannot be isolated. The product is commercially relevant as a specialty hospital drug, but it is unlikely to be a major driver of Shionogi's overall financial trajectory, which is dominated by anti-infective products, HIV royalties, and newer infectious-disease assets.
What is lusutrombopag and how does Mulpleta work?
Lusutrombopag is an oral small-molecule thrombopoietin receptor agonist. It stimulates megakaryocyte proliferation and platelet production through the thrombopoietin receptor pathway.
The FDA approved Mulpleta in July 2018 for adults with chronic liver disease and thrombocytopenia who are scheduled to undergo a procedure. The recommended regimen is 3 mg orally once daily for seven days, with the procedure performed between days 9 and 14 after treatment begins. Patients should not receive the drug to normalize platelet counts in the absence of a scheduled procedure. (FDA, 2018)
This positioning limits the treated population but provides a clear clinical use case:
| Attribute |
Mulpleta |
| Active ingredient |
Lusutrombopag |
| Manufacturer |
Shionogi |
| US brand |
Mulpleta |
| Drug class |
Oral thrombopoietin receptor agonist |
| Approved US use |
Periprocedural thrombocytopenia in adults with chronic liver disease |
| Standard dose |
3 mg once daily for seven days |
| Treatment duration |
Short course |
| Administration |
Oral |
| Main comparator |
Platelet transfusion |
| Key competing drug |
Avatrombopag, marketed as Doptelet |
When did FDA approve lusutrombopag?
The FDA approved Mulpleta on July 31, 2018. Approval was based primarily on the L-PLUS 1 and L-PLUS 2 clinical programs, which evaluated avoidance of platelet transfusion and rescue treatment for bleeding in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures. (FDA, 2018)
Japan approved lusutrombopag earlier, and the product became part of Shionogi's Japanese specialty portfolio before the US launch. The Japanese indication also focuses on thrombocytopenia associated with chronic liver disease before invasive procedures.
Lusutrombopag's regulatory profile has four commercial implications:
- The indication is specific and easy to define for clinical protocols.
- The seven-day regimen limits cumulative drug exposure.
- The product competes directly with transfusion services and hospital logistics.
- The indication does not cover chronic immune thrombocytopenia, limiting expansion into a larger hematology market.
How large is the market for lusutrombopag?
The addressable market consists of patients with chronic liver disease, clinically meaningful thrombocytopenia, and a planned invasive procedure. The market is smaller than the overall thrombocytopenia market because many patients do not require a procedure, have platelet counts above the treatment threshold, or are managed with transfusion or local procedural techniques.
Demand is supported by several trends:
- Growth in the diagnosed population with cirrhosis and advanced liver disease.
- Expansion of interventional radiology, hepatology, and endoscopic procedures.
- Greater use of outpatient procedural pathways.
- Hospital efforts to reduce platelet transfusion dependence.
- Demand for oral alternatives that can be scheduled before elective procedures.
The market is constrained by:
- Short treatment duration and limited repeat use.
- Variable procedural practices across hospitals.
- Reimbursement sensitivity.
- Physician familiarity with platelet transfusion.
- Competition from avatrombopag.
- The absence of a chronic-use indication.
Lusutrombopag is therefore a focused specialty product rather than a broad hematology franchise.
How does lusutrombopag compare with avatrombopag?
Avatrombopag is the principal branded competitor in the same pre-procedure chronic liver disease segment. Doptelet is marketed by Dova Pharmaceuticals, which became part of Swedish Orphan Biovitrum, or Sobi, through Sobi's acquisition of Dova in 2019. Avatrombopag also has an indication for chronic immune thrombocytopenia, giving it a broader commercial platform than Mulpleta. (Sobi, 2019)
| Commercial factor |
Lusutrombopag |
Avatrombopag |
| Brand |
Mulpleta |
Doptelet |
| Chronic liver disease procedure use |
Yes |
Yes |
| Chronic immune thrombocytopenia use |
No US approval |
Yes |
| Typical pre-procedure course |
Seven days |
Five days in the US label |
| Commercial owner |
Shionogi |
Sobi |
| Primary competitive advantage |
Established periprocedural profile and oral dosing |
Broader label and shorter course |
| Main substitution risk |
Avatrombopag and transfusion |
Lusutrombopag and transfusion |
Both drugs reduce the need for platelet transfusion and rescue therapy in selected patients. Product selection may depend on platelet baseline, procedure timing, payer policy, hospital formulary placement, physician experience, and the availability of transfusion services.
Avatrombopag's immune thrombocytopenia indication gives it a stronger opportunity for recurring revenue. Lusutrombopag's short-course model produces episodic sales tied to procedures.
What is the financial trajectory of Mulpleta?
Mulpleta's financial trajectory is likely stable but limited in scale relative to Shionogi's consolidated business. Shionogi reports major product and royalty categories, but Mulpleta is not generally presented as a separately disclosed high-revenue product in its public financial reporting. As a result, standalone annual sales, operating margin, and geographic contribution cannot be derived from Shionogi's consolidated statements.
Shionogi's broader financial performance has been driven by products and royalty streams such as Xofluza, F. Hoffmann-La Roche's HIV products based on Shionogi technology, and newer infectious-disease medicines. Mulpleta is commercially important within Shionogi's specialty portfolio but does not appear to have the scale of those principal revenue contributors. (Shionogi, 2024)
The product's financial profile has several defining characteristics:
Revenue model
Mulpleta generates prescription revenue from a defined procedural event. A patient generally receives one seven-day course rather than continuous treatment. Revenue is therefore episodic, with volume linked to procedure counts and adoption rates.
Margin profile
An oral small molecule with a short course can have favorable gross margins compared with transfusion-dependent care, although net realized price depends on payer contracts, hospital purchasing channels, rebates, and distribution arrangements.
Growth ceiling
The label limits the maximum addressable population. Revenue growth depends more on market penetration, geographic expansion, and procedural conversion than on treatment duration or chronic patient accumulation.
Exposure to competitive pricing
A branded competitor with a shorter regimen and broader indication can pressure formulary access and discounting. Mulpleta also competes against the economic cost of platelet transfusion, which may be lower in some hospital systems.
Which factors drive lusutrombopag sales?
Procedure volume
Sales rise with the number of liver-related procedures performed in patients with thrombocytopenia. Interventional radiology and gastroenterology are central demand channels.
Platelet transfusion avoidance
Clinical and economic value depends on whether hospitals view transfusion avoidance as sufficiently valuable to justify branded drug acquisition. The product is more attractive where platelet inventory is constrained or transfusion creates scheduling delays.
Formulary adoption
Hospital pharmacy committees, hepatology departments, procedure centers, and integrated delivery networks influence utilization. Protocol-based use can improve consistency, while decentralized prescribing can slow adoption.
Reimbursement
Coverage varies by payer and site of care. Prior authorization, specialty pharmacy requirements, and hospital buy-and-bill economics can affect prescription conversion.
Liver disease epidemiology
The prevalence of cirrhosis, hepatocellular carcinoma, hepatitis C, alcohol-associated liver disease, and metabolic dysfunction-associated steatotic liver disease supports the underlying procedure population. Epidemiologic growth does not translate directly into Mulpleta sales because only a subset has severe thrombocytopenia and a qualifying procedure.
What patents protect lusutrombopag?
Lusutrombopag is protected, or was protected, through a combination of compound, pharmaceutical composition, formulation, and use-related intellectual property. The commercially relevant protection categories include:
- The active chemical entity.
- Oral tablet compositions.
- Methods for increasing platelet counts.
- Use in patients with chronic liver disease and thrombocytopenia.
- Periprocedural administration before invasive procedures.
- Manufacturing and crystalline-form claims, where applicable.
The patent estate should be analyzed separately in the United States, Japan, Europe, and other commercial markets because expiration dates, patent-term adjustments, supplementary protection certificates, and regulatory exclusivity differ by jurisdiction.
The principal commercial IP risk is not only early generic entry. A competitor could also challenge a method-of-use or formulation patent while accepting that the underlying compound patent has expired. For a short-course drug, formulation and use claims may be particularly relevant because the approved commercial value depends on the dosing schedule and patient population.
What is the Orange Book status of Mulpleta?
Mulpleta is an FDA-approved prescription product. The FDA's Orange Book is the controlling source for current US patent and exclusivity listings, including listed patents, expiration dates, pediatric exclusivity, and any approved generic applications. (FDA, 2024)
Publicly available commercial information does not indicate an established US generic market for lusutrombopag. The key US entry questions are:
- Whether active Orange Book patents remain listed.
- Whether any abbreviated new drug application has been approved.
- Whether a prospective applicant has submitted a Paragraph IV certification.
- Whether Shionogi has filed patent litigation under the Hatch-Waxman framework.
- Whether settlement terms permit an agreed launch date.
A Paragraph IV challenge would create litigation exposure for the listed patent holder and could delay approval through the statutory 30-month stay if litigation is filed within the applicable period. No confirmed, commercially material Paragraph IV settlement is established in the public record reviewed for this analysis.
When does lusutrombopag lose exclusivity?
The answer differs by jurisdiction and by the type of protection.
FDA approval in 2018 created regulatory exclusivity separate from patent protection. New-drug exclusivity for a conventional small molecule is generally five years, subject to the statutory rules governing abbreviated applications. That period is distinct from patent terms and does not by itself determine the date of generic launch.
The practical US loss-of-exclusivity date depends on the latest enforceable patent and any pediatric extension, patent-term adjustment, litigation stay, or settlement. The FDA Orange Book and USPTO records must be read together to establish the legally operative date. A simple reference to the 2018 approval date is not sufficient to calculate generic entry.
In Japan and Europe, the relevant analysis includes national patent expiry, supplementary protection certificates, data exclusivity, and local generic or hybrid application rules.
Is biosimilar risk relevant to lusutrombopag?
No. Lusutrombopag is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic substitution through an abbreviated application pathway, not biosimilar competition under the Biologics Price Competition and Innovation Act.
This distinction matters commercially. Generic applicants may challenge listed composition, formulation, or method-of-use patents, while biosimilar applicants would not be relevant to the product's entry framework.
What litigation and settlement risks affect Mulpleta?
The main litigation risks are conventional small-molecule Hatch-Waxman risks:
- Paragraph IV patent challenges.
- Declaratory judgment actions involving patent scope or listing.
- Patent-term disputes.
- ANDA litigation concerning tablet composition or therapeutic use.
- Antitrust scrutiny of any reverse-payment or delayed-entry settlement.
No major public US patent litigation involving Mulpleta is established as a current market-moving event in the available record. The absence of reported litigation does not eliminate future entry risk. It indicates that the commercial landscape has not, to date, been reshaped by a disclosed generic challenge.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate rather than extreme. Lusutrombopag is a small molecule supplied as an oral tablet, so it does not face the complex cell-line, comparability, cold-chain, or biosimilar manufacturing issues associated with biologics.
Potential barriers include:
- Development of a bioequivalent tablet.
- Control of impurities and solid-state properties.
- Reliable active pharmaceutical ingredient supply.
- Validation of dissolution and stability.
- Ability to support the product's specific strength and packaging.
- Patent exposure relating to composition, crystalline form, or manufacturing process.
The short treatment course reduces demand for large production capacity. That factor can make generic entry operationally manageable once regulatory and patent barriers are resolved.
What generic launch scenarios exist for lusutrombopag?
Delayed generic entry
A generic applicant may wait until relevant patents expire or launch after a negotiated settlement. This scenario preserves branded pricing but limits long-term volume growth.
Paragraph IV litigation
A challenger may seek approval before patent expiry by asserting invalidity, unenforceability, or non-infringement. The outcome would depend on the specific patents listed and the claims asserted.
At-risk launch
A generic company could launch before final patent resolution, accepting potential damages or injunction risk. This is less attractive when the product's total market is modest.
Authorized or licensed competition
Shionogi could license a regional partner or authorize a second source. This would expand distribution but could reduce net price and internal sales.
For Mulpleta, a delayed generic entry is commercially plausible because the market is specialized, hospital-oriented, and smaller than large chronic-use drug categories. A challenger would likely need a clear path to formulary access and sufficient volume to justify litigation and launch costs.
How exposed is Shionogi to Mulpleta revenue loss?
Shionogi's consolidated exposure appears limited because Mulpleta is not reported as a major standalone revenue pillar. The product could still matter to the company's specialty portfolio, Japanese operations, and relationships with hepatology and hospital customers.
Revenue loss from generic entry would likely be concentrated in:
- US branded sales.
- Japanese branded sales.
- Specialty distribution margins.
- Procedure-center formulary contracts.
- Any regional licensing income.
The impact would be materially smaller than the loss of a major global franchise. Mulpleta's financial importance is better assessed as a portfolio contribution and strategic specialty asset than as a central valuation driver.
Key Takeaways
- Lusutrombopag is a short-course oral thrombopoietin receptor agonist for periprocedural thrombocytopenia in adults with chronic liver disease.
- Mulpleta was approved by the FDA in 2018 and is marketed by Shionogi.
- The commercial market is defined, episodic, and smaller than the chronic immune thrombocytopenia market.
- Avatrombopag, marketed as Doptelet by Sobi, is the main branded competitor and has a broader US indication.
- Shionogi does not publicly disclose Mulpleta as a separate major revenue line.
- Generic, not biosimilar, competition is the relevant long-term risk.
- The decisive loss-of-exclusivity date depends on active Orange Book patents, patent-term adjustments, pediatric extensions, litigation, and settlements.
- Mulpleta is unlikely to represent a major consolidated financial vulnerability for Shionogi, but generic entry could materially affect the product's specialty-market economics.
FAQs About Lusutrombopag Market and Financial Outlook
Does lusutrombopag have a chronic immune thrombocytopenia indication?
No. In the United States, Mulpleta is approved for adults with chronic liver disease and thrombocytopenia who are scheduled for an invasive procedure. It is not approved for chronic immune thrombocytopenia.
Is Mulpleta used before liver biopsy or endoscopy?
It may be used before qualifying invasive procedures when the patient has chronic liver disease and thrombocytopenia, subject to the FDA-approved label and physician judgment. The label does not authorize indiscriminate use before every procedure.
Who owns the Mulpleta brand?
Shionogi owns and markets Mulpleta in the United States. Regional commercialization rights may differ by jurisdiction.
Can platelet transfusion be used instead of lusutrombopag?
Yes. Platelet transfusion remains an established alternative. The commercial value of lusutrombopag depends partly on whether it reduces transfusion use, procedure delays, and transfusion-related resource requirements.
Is lusutrombopag a high-growth pharmaceutical asset?
It is more accurately classified as a focused specialty asset. Growth depends on penetration of the periprocedural chronic liver disease market, procedure volumes, reimbursement, and competitive positioning against avatrombopag. Its short-course design limits recurring revenue per patient.
References
-
Food and Drug Administration. (2018). Mulpleta (lusutrombopag) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Shionogi & Co., Ltd. (2024). Annual report and financial results materials. Osaka, Japan.
-
Sobi. (2019). Sobi completes acquisition of Dova Pharmaceuticals. Stockholm, Sweden.
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Studies of lusutrombopag in chronic liver disease-associated thrombocytopenia. National Institutes of Health.
